Rhythm Pharmaceuticals (RYTM) Income towards Parent Company (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Income towards Parent Company for 11 consecutive years, with -$55.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 12.27% year-over-year to -$55.6 million; the TTM figure through Mar 2026 stood at -$202.6 million (down 20.04% YoY), while the FY2025 annual figure was -$196.5 million, up 24.58% from the prior year.
• Income towards Parent Company eased to -$55.6 million in Q1 2026 per RYTM's latest filing, from -$47.5 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$32.3 million in Q2 2024 and bottomed at -$141.4 million in Q1 2024.
• Historically, Income towards Parent Company has averaged -$52.0 million across 5 years, with a median of -$46.7 million in 2023.
• Annual changes were most pronounced in 2022 — Income towards Parent Company plunged 226.48% — and 2025, when it jumped 64.97%.
• Rhythm Pharmaceuticals' Income towards Parent Company stood at -$42.5 million in 2022, then rose by 2.02% to -$41.6 million in 2023, then dropped by 4.07% to -$43.3 million in 2024, then declined by 9.64% to -$47.5 million in 2025, then retreated by 17.03% to -$55.6 million in 2026.
• Business Quant data shows RYTM's Income towards Parent Company at -$55.6 million in Q1 2026, -$47.5 million in Q4 2025, and -$52.9 million in Q3 2025.